DEVELOPMENT OF AN IMPROVED SMALL DIAMETER VASCULAR GRAFT

三十多年来，血管外科的一个主要目标是 通过开发一种理想的 人工移植物 虽然大隐静脉是首选 基质闭塞的小到中等静脉，往往是 不适用于或不适合大量需要的患者 这个手术 其中两个问题损害了 这种移植物发展包括细胞附着不良， 接种移植物和暴露时移植物对细胞的保留较差 到体外或体内流动条件。 虽然使用 纤连蛋白导致了一些改善， 这些参数，移植物的发展仍然很远， 完成. 本文介绍了贻贝粘附蛋白的实验研究 (MAP，BioPolymers，Inc. 法明顿，CT）。 这种蛋白质具有 在体外和体内增加细胞与移植物粘附的潜力 vivo. 已经发现MAP作为细胞附着有效 因子，并且与细胞和组织生物相容。 实验旨在探索附着效率的 细胞移植和保留这些细胞的移植期间 灌注。

For over thirty years, a major goal of vascular surgery has been to improve bypass surgery through the development of an ideal prosthetic graft. Although saphenous vein is the preferred substrate for occluded small to medium veins, frequently it is unavailable or unsuitable to a great number of patients who need this surgery. Two of the problems that have impaired the development of such a graft include poor cell attachment upon seeding grafts and poor retention of cells by grafts when exposed to in vitro or in vivo flow conditions. Although the use of fibronectin has resulted in some improvements with respect to these parameters, development of grafts is still far from complete. This proposal describes experiments on mussel adhesive protein (MAP, BioPolymers, Inc. Farmington, CT). This protein has the potential to increase the adhesion of cells to grafts in vitro and in vivo. MAP has been found to be effective as a cell attachment factor in vitro and is biocompatible with cells and tissues. Experiments are designed to explore attachment efficiency of cells to grafts and the retention of these cells by grafts during perfusion.